Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

25 November 2021

Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 5 ..

22 November 2021

Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support S..

19 November 2021

Pfizer and BioNTech Receive Expanded U.S. FDA Emergency Use Authorization of CO..

Press releases (more)

Upcoming Events

January 10 - January 13, 2022

J.P. Morgan Healthcare Conference

Upcoming events (more)

Stock Quote

Dec 4, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.